These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15851788)

  • 1. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 2. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic colorectal cancer: adjournments from ESMO 2006].
    Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
    Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 5. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progress of chemotherapy in colorectal cancer].
    Komatsu Y
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
    [No Abstract]   [Full Text] [Related]  

  • 7. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Pohlmann PR; Mernaugh RL; Goff LW
    N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
    [No Abstract]   [Full Text] [Related]  

  • 9. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
    Doi T; Ohtsu A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 12. [Systemic therapy for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 14. Progress in the development of novel treatments for colorectal cancer.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic colorectal cancer: is there one standard approach?
    Saltz LB
    Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
    [No Abstract]   [Full Text] [Related]  

  • 17. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
    Muro K
    Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Copur MS; Norvell M; Obermiller A
    N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.